http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#Head
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#assertion
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#provenance
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#pubinfo
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#assertion
http://purl.obolibrary.org/obo/DOID_1040
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_1040
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB06650
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association
http://www.w3.org/2000/01/rdf-schema#label
chronic lymphocytic leukemia cll arzerra ofatumumab is indicated in combination with chlorambucil for the treatment of previously untreated patients with cll for whom fludarabine based therapy is considered inappropriate see clinical studies 14 1 in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed cll see clinical studies 14 2 for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive cll see clinical studies 14 3 for the treatment of patients with cll refractory to fludarabine and alemtuzumab see clinical studies 14 4 arzerra ofatumumab is a cd2 directed cytolytic monoclonal antibody indicated for the treatment of chronic lymphocytic leukemia cll 1 in combination with chlorambucil for the treatment of previously untreated patients with cll for whom fludarabine based therapy is considered inappropriate in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed cll for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive cll for the treatment of patients with cll refractory to fludarabine and alemtuzumab
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB06650
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#provenance
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#pubinfo
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#sig
http://purl.org/nanopub/x/hasSignature
FKvGJ9o9bSfijSgwpIvb6s1Y90NuK6aE4jihBMEOzY+BJwpBcQB/9P7/ugJzvpKRmG0qSvfsSZ9+lSj7v4OY+Zgz2d+c3ZvBfOdUWwrR+DrWWdDA17qdqXGKyEheG/+vFTlWIe1ftC37KQsNBqymY1FKmRIOCXfXKeBE7YVhrdY=
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE
http://purl.org/dc/terms/created
2021-07-03T14:56:16.700+02:00
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs